Phase 3 Trial Initiated to Evaluate Liraglutide's Renal Outcomes in Diabetic Kidney Disease

Diabetic kidney disease (DKD) represents a severe complication of diabetes, often progressing to end-stage renal disease, requiring dialysis or transplantation, and significantly increasing the risk of cardiovascular mortality. Current standard-of-care, primarily focusing on glycemic and blood pressure control, including renin-angiotensin-aldosterone system (RAAS) inhibitors, often falls short in fully halting disease progression. Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of diabetes medications that have shown promise beyond glycemic control, with preclinical evidence suggesting anti-inflammatory and renoprotective effects, making them a compelling area for investigation in DKD.

This randomized, controlled Phase 3 clinical trial (NCT01847313) enrolled 20 human participants diagnosed with diabetic kidney disease. The study aimed to compare the effects of liraglutide against standard diabetes care. Participants in the active arm received Liraglutide 0.6 mg daily via subcutaneous administration for a duration of 6 months. The control arm received standard diabetes care, which included a renin-angiotensin-aldosterone system (RAAS) inhibitor or antagonist. The primary objective was to monitor the effect on inflammation and kidney function using blood and urine tests.

This abstract describes the design and rationale for a Phase 3 clinical trial investigating liraglutide's effects on diabetic kidney disease. However, the provided summary and domain context do not include any specific results, numerical data, p-values, or statistical outcomes from the completed study. Therefore, no findings can be reported from this abstract. The study was completed in November 2015, but the results have not been made available in the provided text.